BioNeex
BioNeex is an AI-powered two-sided marketplace that connects biotech and drug development companies with biopharmaceutical partners and venture capital investors to license, co-develop, and invest in therapeutic assets, serving 300+ clients globally.
- Company typePrivate
- Founded2021
- HeadquartersSyracuse, United States
- Headcount11–50
- GTM typeB2B
- OfferingDigital Commerce or Content
What BioNeex does
BioNeex (Bioneex, Inc.) is an AI-powered, two-sided marketplace platform that connects drug development companies — primarily emerging biotech firms listing therapeutic assets — with strategic biopharmaceutical partners and venture capital investors for licensing, co-development partnerships, and investments. Founded in 2021 (per primary press release sources) and headquartered in Syracuse, NY, with additional operations in San Francisco, the company operates a cloud-based SaaS platform that serves over 300 biotech and biopharma clients globally, including named enterprise participants Johnson & Johnson, Bayer, AbbVie, GSK, BioNTech, and biotech-focused VC firms Sofinnova Partners, Curie.Bio, Andera Life Sciences, Apple Tree Partners, TVM Capital Life Science, and ALSA Ventures. The platform is governed by a Delaware-incorporated entity with Terms of Use restricting access from the EEA, UK, and Canada.
BioNeex's product surface consists of three layered components: (1) the core Bioneex Marketplace Platform, which supports asset listings, search, evaluation, and direct connection between biotech listers and biopharma/VC reviewers; (2) the Search & Evaluation (S&E) AI Agent, launched August 2025, which autonomously reviews proprietary biotech decks, global patents, scientific publications, clinical trial databases, and regulatory filings to identify opportunities and assess strategic fit; and (3) Derisq™, a trademarked investor confidence tool offered in partnership with GATC Health (integrated September 2025), which applies human systems biology AI models to predict drug candidate safety, efficacy, and off-target effects with third-party-validated accuracy of 91% true positive and 86% true negative from University of California, Irvine studies. BioNeex also offers custom enterprise AI Agent solutions that integrate a client's internal R&D, Search & Evaluation, and Business Development datasets into the platform.
The company monetizes through a dual fee structure. Asset-listing biotech companies can elect either an annual, non-refundable subscription fee (Fee Option 1) or a success fee on upfront payments received from transactions facilitated through the platform (Fee Option 2), with success fees payable within 30 days of receipt. Reviewing entities — established biopharma companies, VC firms, and family offices — access the platform under separate Platform Access Agreements with their own annual subscription terms; specific pricing is not publicly disclosed. BioNeex is privately held and venture-backed, having raised approximately $1 million across an angel round from BANA Angels (2023) and an oversubscribed $0.5 million seed round led by former Pfizer and Amgen executives in February 2024, at which time it concurrently launched a $6 million follow-on funding round. The company is led by Founder and CEO Dr. Smbat Rafayelyan and CTO Edgar Marukyan (appointed February 2024, previously at Renderforest), with an advisory board drawing from major pharmaceutical companies and venture capital firms.
BioNeex firmographics
Firmographics- Name
- BioNeex
- Legal name
- Bioneex, Inc.
- Website
- https://bioneex.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioNeex is an AI-powered two-sided marketplace that connects biotech and drug development companies with biopharmaceutical partners and venture capital investors to license, co-develop, and invest in therapeutic assets, serving 300+ clients globally.
- Ownership category
- akta.pro rank
BioNeex industry classification
Industry- Product category
- Biopharma R&D Marketplace
- NAICS
- Software Publishers (5132), Software Publishers (51321)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
Keywords
Where BioNeex is headquartered
LocationHeadquarters
- HQ city
- Syracuse
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioNeex business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Annual Subscription Fee (Fee Option 1): Users can pay an annual non-refundable subscription fee to access the Platform. Users with this option are not subject to any success fee or transaction-based fee for transactions completed through the Platform during the subscription period.
- Success Fee (Fee Option 2): Users can elect to pay no annual subscription fee. Instead, upon successful execution of a transaction facilitated through the Platform, the User agrees to pay Bioneex a success fee generally based upon the upfront payment received as part of any licensing or co-development agreement.
- Platform Access Agreement Fees: Established biopharmaceutical companies, venture capital firms, family offices, and other entities that access the Platform to search for and evaluate listed therapeutic assets pay an annual subscription fee pursuant to a separate Platform Access Agreement.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Annual Subscription Fee - Option 1 |
| Transaction based/ take rate | Pay-as-you-go | Success Fee - Option 2 |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
BioNeex product offering
Product offeringCore offering
BioNeex operates an AI-powered two-sided marketplace platform that connects drug development companies (listing therapeutic assets) with strategic biopharma partners and venture capital investors (evaluating and acquiring those assets). The platform facilitates licensing deals, co-development partnerships, and investments by combining proprietary biotech data, global patents, scientific publications, and competitive intelligence with AI-driven search, evaluation, and predictive risk analytics.
Product overview
Bioneex is an AI-powered platform consisting of a core marketplace (the Bioneex AI-Powered Marketplace Platform) that connects drug development companies with biopharma partners and venture capital investors for licensing, co-development, and investment. Built on top of this core are AI-powered tools including the Search & Evaluation (S&E) AI Agent for automated asset scouting and due diligence, and Derisq™ (in partnership with GATC Health) for predictive risk analysis of drug candidates. The platform serves both asset-listing biotech companies and asset-evaluating biopharma/VC firms via subscription-based SaaS plans. Notable clients include Johnson & Johnson, Bayer, AbbVie, GSK, BioNTech, and multiple VC firms.
Differentiator
Problem solved
Functional benefit
Brands
- Derisq™: Market-first investor confidence tool offered in partnership with GATC Health. GATC's AI platform leverages human systems biology AI models to predict sensitivity and specificity with >85% precision while identifying off target effects.
Products and services
- Bioneex AI-Powered Marketplace Platform
- Derisq™
- Search & Evaluation (S&E) AI Agent
- Custom Enterprise AI Agent Solutions
Quantifiable outcome
- Validated drug candidate prediction accuracy: 91% true positive rate, 86% true negative rate (University of California, Irvine validation)
Companies that use BioNeex
Customer profileNamed customers11 records
Segments4 records
Ideal customer profiles3 records
BioNeex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability6 records
Feature4 records
BioNeex partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- GATC HealthcoreStrategic partnership integrating GATC Health's AI-driven predictive analytics into Bioneex's marketplace platform. The integration provides advanced predictions of drug candidate performance including safety, efficacy, and off-target effects with validated accuracy rates of 91% true positive and 86% true negative. This collaboration enables data-driven asset prioritization and clinical trial optimization for biopharma companies and venture capital investors.
- TVM Capital Life ScienceflagshipPartnership to launch a Global Forum bringing together biotech companies and venture capital firms. The collaboration increases investment and drug candidate licensing and partnership opportunities for biotech and biopharma companies by listing their drug candidates on Bioneex and connecting directly with potential licensing and co-development partners as well as investors.
- ALSA VenturescorePartnership to provide biotech firms with a new way to drug candidate out-licensing and acquiring investment. Biotech companies, biopharma companies, and research institutions list their drug candidates on Bioneex to connect directly with potential licensing and co-development partners as well as investors.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
BioNeex competitors and assessment
Company assessmentEmerging players
- Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company with generative biology and predictive platforms. It is an emerging player with thematic overlap to the GATC Health/Derisq layer of BioNeex and could compete directly with the predictive AI feature over time.
- AlphaSense: AlphaSense is an enterprise market intelligence and search platform used by biopharma corporate strategy and BD teams for external research and competitive monitoring. It is an emerging adjacent player competing for a portion of BioNeex's buyer budget.
- BenchSci: BenchSci applies AI to biomedical literature and experimental data to accelerate preclinical R&D. It is an emerging player with thematic overlap to BioNeex's AI-for-pharma-R&D positioning and is referenced in industry analyses of the GenAI-in-pharma landscape.
Direct peers
- DealForma: DealForma is a biopharma deal intelligence and licensing platform that tracks M&A, licensing, and partnership transactions. It is the closest direct competitor to BioNeex's marketplace offering, addressing the same pharma BD/S&E buyer persona with a database-and-workflow product.
- PharmaCircle: PharmaCircle is a pharma business intelligence platform covering pipelines, licensing, and commercial data for biopharma professionals. It is a direct peer to BioNeex in serving pharma BD and competitive intelligence workflows.
Broad incumbents
- BioCentury: BioCentury is a long-established biopharma intelligence publisher covering licensing deals, pipelines, and strategy across the industry. It is a broad incumbent that serves the same biopharma BD/S&E buyer base as BioNeex, with deeper editorial coverage but without a two-sided marketplace layer.
- Citeline (formerly Pharma Intelligence): Citeline, owned by Norstella, provides pharma pipeline, clinical trial, and commercial intelligence used by enterprise pharma BD/S&E teams. It is a broad incumbent that competes for the same buyer budget as BioNeex with deeper historical data assets.
- Evaluate (EvaluatePharma): Evaluate provides pharma market intelligence, forecasting, and deal data to enterprise biopharma. It competes for the same pharma analytics/BD budget as BioNeex and represents a major incumbent in the therapeutic-asset intelligence category.
- Informa Pharma Intelligence: Informa Pharma Intelligence offers pipeline, trial, and commercial intelligence to pharma BD/S&E teams. It is a broad incumbent and a viable alternative buyer destination for the enterprise pharma BD budget that BioNeex targets.
- GlobalData Pharmaceutical: GlobalData provides syndicated pharma intelligence covering pipelines, deals, and commercial outlook. It is a broad incumbent that competes for the same enterprise pharma BD/strategy budget as BioNeex.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
BioNeex social profiles
Digital presenceBioNeex financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioNeex leadership team
Management profileNumber of profiles
Profiles2 records
BioNeex funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioNeex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioNeex
What does BioNeex do?
BioNeex operates an AI-powered two-sided marketplace platform that connects drug development companies (listing therapeutic assets) with strategic biopharma partners and venture capital investors (evaluating and acquiring those assets). The platform facilitates licensing deals, co-development partnerships, and investments by combining proprietary biotech data, global patents, scientific publications, and competitive intelligence with AI-driven search, evaluation, and predictive risk analytics.
Is BioNeex a public or private company?
BioNeex is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioNeex founded?
BioNeex was founded in 2021. It employs 11 to 50 people.
Where is BioNeex based?
BioNeex is headquartered in Syracuse, United States, in the North America region.
How does BioNeex make money?
Three revenue lines are on record. Annual Subscription Fee (Fee Option 1) is the primary driver. The others are success Fee (Fee Option 2) and platform Access Agreement Fees.
Who are BioNeex's main competitors?
Emerging players on record are Insilico Medicine, AlphaSense and BenchSci. Direct peers are DealForma and PharmaCircle. Broad incumbents are BioCentury, Citeline (formerly Pharma Intelligence), Evaluate (EvaluatePharma), Informa Pharma Intelligence and GlobalData Pharmaceutical.
Does BioNeex have an API?
No public API is recorded for BioNeex.
What industry is BioNeex in?
BioNeex's product category is Biopharma R&D Marketplace. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 5132.